Navigation Links
Blue Medical Receives European CE Mark Approvals for Drug Eluting Balloon and Stent on Drug Eluting Balloon Combination Device
Date:11/16/2010

Blue Medical Receives European CE Mark Approvals for Drug Eluting Balloon... -- HELMOND, The Netherlands, November 16, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Equipment, Medical Pharmaceuticals, Awards, Licensing Click to view news release full screen  

Blue Medical Receives European CE Mark Approvals for Drug Eluting Balloon and Stent on Drug Eluting Balloon Combination Device

 

HELMOND, The Netherlands, November 16, 2010 /PRNewswire/ --

- First Ever CE Approved Combination Device is an Attractive Treatment for Coronary Artery Diseases

Blue Medical today announced that the company received CE Mark approval for Blue Medical science based Drug Eluting Balloon (DEB) and simultaneously for Blue Medical's coronary CoCr stent mounted on a Drug Eluting Balloon (CoCr Stent on DEB) in Europe for treatment of coronary diseases.

DEB therapy delivers a controlled dose of Paclitaxel to the coronary artery during balloon angioplasty. A unique combination of a one-time short and precise drug delivery with DEB during placement of a coronary stent is now for the first time approved and available in Europe.

"Increased late stent thrombosis risk and the long term dual anti-platelet medication which are associated with the majority of current drug eluting stents is a concern in treating our patients today," said Primary Investigator of the PIONEER Study Peter Smits, M.D., head of Intervention Cardiology at the Maasstad Hospital, Rotterdam, The Netherlands. "DEB therapy in combination with bare metal coronary stents offers a potential solution for reducing late lumen loss without the need for long term dual-anti-platelet medication, improving patent comfort and reducing risks for bleeding and stent thrombosis."

The CE Mark approval is based on extensive in-vivo research performed world-wide and preliminary data collected in Blue Medical's clinical trial, PIONEER. Based on the CE mark, Blue Medical will introduce the CoCr stent on DEB, called Pioneer and its DEB, called Protege across Europe by the end of the year.

"This CE Mark is the first approval by a regulatory agency for the use of DEB therapy in combination with a bare metal stent and provides a new attractive treatment for patients in Europe who are in need of other options," said Ronald Horvers, CEO of Blue Medical. "We worked closely with the respected Dutch competent authority CBG and with KEMA as notified body to ensure a solid science base for this CE approval."

About Blue Medical

Blue Medical (http://www.bluemedical.com), headquartered in Helmond, The Netherlands, is a global medical devices company and innovator in treatment of cardiovascular diseases. The company develops, manufactures and markets innovative products for vascular diseases extending life for over 75,000 patients worldwide annually.


'/>"/>
SOURCE Blue Medical Devices BV
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Globus Medical Raises $110 Million in Series E Financing Round
5. Quark Pharmaceuticals Appoints New Chief Medical Officer
6. Boston University Biomedical Engineers Find Chink in Bacterias Armor
7. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
8. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
9. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
10. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
11. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , Feb. 8, 2016  Ventana Medical ... that hundreds of the world,s top oncologists, pathologists, ... at the 12 th annual Tucson Symposium ... evolving theories and new outcomes in cancer research ... patients, lives. Thomas Grogan , annually ...
(Date:2/8/2016)... 2016 Nueterra, the nation,s largest ... the development of equity partnerships and focused ... divided its interests between two new companies—NueHealth ... continue the founding company,s private equity investment ... national system of integrated provider networks that ...
(Date:2/8/2016)... , Feb. 8, 2016 ... "Knee Reconstruction Devices Market by Product Type ... and Geography (U.S., Canada, Eu-5, Japan, Bric, Turkey, ... report to their offering. --> ... the "Knee Reconstruction Devices Market by Product ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... Coast Dental has a new way to help ... Month and family dentist Yvonne Dorrian, DMD, is hosting a free seminar on Friday, ... next to Target at 1207 North Peachtree Parkway in Peachtree City. Dr. Dorrian will ...
(Date:2/8/2016)... ... ... who has struggled to quit smoking, a man who has struggled with hair loss – ... his problems – and he did. Now Nabat, a serial entrepreneur featured as the October ... to the world and better people's lives. His own experience with nicotine addiction led to ...
(Date:2/8/2016)... ... February 08, 2016 , ... Tingley Rubber Corporation , ... provide its range of unique and advantaged protective solutions to a growing ... provide bilingual customer service and marketing support. A new distribution center in Brampton, ...
(Date:2/8/2016)... ... 08, 2016 , ... Local insurance agency Dennis Fuller & ... has initiated a fundraiser for a two year old little girl named Bella, ... To support this beautiful child who is facing life’s journey without her loving ...
(Date:2/8/2016)... ... , ... Remember the old saying “rub some dirt on it”? Perhaps you ... “Calcium Bentonite Clay” the health benefits of integrating clay into a daily diet are ... A former motivational speaker, Perry A~ has since dedicated her life to learning about ...
Breaking Medicine News(10 mins):